News

VRTX Q2 2025 Deep Dive: New Product Launches and Pipeline Update in a Volatile Market

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.96 billion. The company expects the ...

The 5 Most Interesting Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...